Bone metabolism drugs (bisphosphonates, RANKL inhibitors)

Bone Remodeling - The Osteo Tango

• Osteoblasts (Build): Synthesize bone matrix (osteoid). Regulated by Wnt pathway.
• Osteoclasts (Chew): Multinucleated cells that resorb bone by secreting acid and collagenases.
• The Tango (RANK/RANKL Axis):
  • RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) on osteoblasts binds to RANK on osteoclast precursors.
  • This interaction drives osteoclast differentiation and activation, leading to ↑ bone resorption.
  • Osteoprotegerin (OPG): A decoy receptor produced by osteoblasts; it binds RANKL, preventing resorption.

⭐ Denosumab is a monoclonal antibody that mimics OPG by binding to RANKL, thus inhibiting osteoclast function. It is used to treat osteoporosis.

Bisphosphonates - Cementing the Bricks

• Mechanism: Pyrophosphate analogs that bind to hydroxyapatite in bone, where they are ingested by osteoclasts, ultimately inducing apoptosis and inhibiting bone resorption.
• Kinetics: Poor oral bioavailability. Must be taken on an empty stomach with plain water, and the patient must remain upright for 30-60 minutes to prevent esophagitis.
• Drugs: Alendronate, Risedronate, Ibandronate, Zoledronic acid (IV).
  • 📌 The "-dronate" suffix is a dead giveaway.
• Uses: Osteoporosis, Paget's disease of bone, hypercalcemia of malignancy, bone metastases.
• Adverse Effects:
  • Erosive esophagitis ⚠️
  • Atypical femoral fractures
  • Hypocalcemia

⭐ Osteonecrosis of the jaw (ONJ) is a well-known, albeit rare, complication, particularly with high-dose IV forms. Often linked to recent dental work.

RANKL Inhibitors - Guarding the Gate

• Drug: Denosumab (monoclonal antibody).

• Mechanism: Binds to RANKL, preventing its activation of the RANK receptor on osteoclasts and their precursors. This action ↓ osteoclast formation, function, and survival, thereby reducing bone resorption.

• Uses:

  • Postmenopausal osteoporosis.
  • Bone loss from hormone ablation therapy for cancer.

• Adverse Effects:

  • ⚠️ Hypocalcemia (must correct pre-treatment).
  • Osteonecrosis of the jaw (ONJ).
  • Atypical femoral fractures.

⭐ High-Yield: Unlike bisphosphonates, denosumab's effects are reversible. Discontinuation can cause a rapid rebound in bone turnover and an ↑ risk of vertebral fractures.

Anabolics & Others - The Bone Builders

• PTH Analogs (Teriparatide, Abaloparatide)

  • MOA: Recombinant PTH or PTHrP analogs. Intermittent (pulsatile) administration stimulates osteoblastic activity more than osteoclastic activity, leading to a net increase in bone formation.
  • Use: Treatment of severe osteoporosis for patients at high risk of fracture.
  • Limit: Lifetime cumulative use is restricted to ≤2 years.
  • ⚠️ Black Box Warning: Increased risk of osteosarcoma. Avoid in patients with Paget's disease of bone or prior skeletal radiation.

• Sclerostin Inhibitor (Romosozumab)

  • MOA: Monoclonal antibody that binds and inhibits sclerostin, a protein that blocks bone formation. This results in a dual effect: ↑ bone formation and ↓ bone resorption.
  • ⚠️ Black Box Warning: May increase the risk of myocardial infarction, stroke, and cardiovascular death.

⭐ Teriparatide's effect is paradoxical: intermittent pulses are anabolic (build bone), whereas continuous high levels of PTH (like in primary hyperparathyroidism) are catabolic (break down bone).

High‑Yield Points - ⚡ Biggest Takeaways

• Insulin lispro/aspart for postprandial glucose; glargine/detemir for basal control.
• Metformin is first-line for Type 2 DM; major risk is lactic acidosis, especially with renal insufficiency.
• Thionamides (methimazole, PTU) block thyroid peroxidase. PTU also inhibits peripheral T4 to T3 conversion.
• Levothyroxine for hypothyroidism requires TSH monitoring due to its narrow therapeutic index.
• Bisphosphonates (alendronate) can cause pill-induced esophagitis and osteonecrosis of the jaw.
• Denosumab, a RANKL inhibitor, decreases osteoclast maturation, reducing fracture risk.